-
Mashup Score: 1Balancing tuberculosis therapy and substance use - 1 year(s) ago
Tuberculosis (TB) is a major cause of illness and death globally, the annual WHO Global TB Report stated that 1·6 million people died from TB in 2022. In South Africa, TB remains the leading cause of death. The focal points of this epidemic are institutions like residential hospital DP Marais, in Cape Town, South Africa, which is the principle setting of Anna Versfeld’s recent book Making…
Source: The Lancet Infectious DiseasesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial - 1 year(s) ago
Adjunctive rosuvastatin at 10 mg once per day was safe but did not produce substantive benefits on culture conversion in the overall study population. Future trials could explore the safety and efficacy of higher doses of adjunctive rosuvastatin.
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New research: Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial https://t.co/At59o69W6x https://t.co/xoOBoIpQvi
-
-
Mashup Score: 0Balancing adjunctive therapy for tuberculosis treatment - 1 year(s) ago
Khethiwe (name changed to protect privacy) did not understand what had been happening to her since she started taking medication for tuberculosis 2 weeks ago. Instead of feeling better—as the doctor promised she would—her fever returned and breathing was harder every day. This could be because she had to take so many tablets on an empty stomach as she was no longer able to work due to her…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
And the linked comment: Balancing adjunctive therapy for tuberculosis treatment https://t.co/J4MR6IUkl9 #WorldTBDay
-
-
Mashup Score: 0
COVID-19 showed the value of international platform trials to produce rapid and robust evidence on the best way to treat and manage patients.1 The COVID-19 pandemic also revealed an urgent need to further improve the clinical trials ecosystem (ie, all elements required to fund, prioritise, design, conduct, monitor, and report scientifically and ethically appropriate, well designed, and well…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New correspondence: International platform trials: as diseases cross borders, so should trials https://t.co/DiuSKV81AJ
-
-
Mashup Score: 0Balancing tuberculosis therapy and substance use - 1 year(s) ago
Tuberculosis (TB) is a major cause of illness and death globally, the annual WHO Global TB Report stated that 1·6 million people died from TB in 2022. In South Africa, TB remains the leading cause of death. The focal points of this epidemic are institutions like residential hospital DP Marais, in Cape Town, South Africa, which is the principle setting of Anna Versfeld’s recent book Making…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New media watch: Balancing tuberculosis therapy and substance use https://t.co/RslaVUNzew
-
-
Mashup Score: 0Promoting diversity and equity in publishing - 1 year(s) ago
As the chief executive officer of Google and its parent company Alphabet, Sundar Pichai said, “A diverse mix of voices leads to better discussions, decisions, and outcomes for everyone”. Diversity, equity, and inclusion (DEI) are important at every stage of the publishing process, from content to authors and editorial teams. Publishing is not a level playing field and not everyone has the same…
Source: The Lancet Infectious DiseasesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Great to see these commitments from our colleagues @TheLancetInfDis! 👏 https://t.co/vM8aEZRYC8
-
-
Mashup Score: 12New boosters are here! Who should receive them and when? - 1 year(s) ago
The FDA has authorised bivalent booster vaccines containing mRNA for the ancestral SARS-CoV-2 variant as well as B.1.1.529.4 (BA.4) and B.1.1.529.5 (BA.5), the latter being the most prevalent omicron subvariant circulating now.
Source: The Lancet Infectious DiseasesCategories: Expert Picks, Latest HeadlinesTweet-
BOOSTERS: US thinking about 6 month booster >65 now vs yearly for older individuals. Here is some data we put together that immunocompromised, older will need the more regular boosting: https://t.co/YJzM7VNd1G and https://t.co/w7zBttWiRT
-
-
Mashup Score: 22New boosters are here! Who should receive them and when? - 1 year(s) ago
The FDA has authorised bivalent booster vaccines containing mRNA for the ancestral SARS-CoV-2 variant as well as B.1.1.529.4 (BA.4) and B.1.1.529.5 (BA.5), the latter being the most prevalent omicron subvariant circulating now.
Source: The Lancet Infectious DiseasesCategories: Expert Picks, Latest HeadlinesTweet-
This article we wrote goes over who is still at risk for severe disease in 2022 after vaccines & high rates of population immunity (citing that excellent Lancet 30 million person UK study after 2 doses): older, those on immunosuppressants, >4 comorbidities https://t.co/YJzM7VNd1G
-
-
Mashup Score: 0
In a setting with high levels of COVID-19 vaccine uptake, nirmatrelvir–ritonavir effectively reduced the risk of hospital admission or death within 30 days of a positive outpatient SARS-CoV-2 test.
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
In a large retrospective cohort study of those “eligible” for paxlovid, the baseline hospitalization rate was 0.9 percent. Most studies coming out now are consistently showing high risk is less than 1% (as compared to 5-6% pre vaccine) https://t.co/yJ7YvBzAfX
-
-
Mashup Score: 5
The most recent estimate of people living with post-COVID-19 condition (also known as long COVID) globally has surpassed 65 million1 and, without clear diagnostic or treatment options available, this number is steadily increasing. There are more than 200 reported symptoms associated with long COVID,1 affecting virtually every organ system.
Source: The Lancet Infectious DiseasesCategories: Future of Medicine, Latest HeadlinesTweet-
It's complicated. High levels of autoantibodies have been demonstrated in some people with #LongCovid. https://t.co/NwXVISGlNd by @VirusesImmunity @PutrinoLab https://t.co/n1hxFYd4Fk by @LabHeath But some of these antibodies appear to be protective 👇 https://t.co/XlgMCwvaWd https://t.co/RvwrsnXAVg
-
RT @TheLancetInfDis: New media watch: Balancing tuberculosis therapy and substance use https://t.co/RslaVUNzew